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the RoB of included studies as high. Both do not describe
a methodology to assess applicability. However, in the CR
applicability is discussed with respect to study medication
and microbiologic methods, but not generally rejected. The
IQWiG report regards interventions in 2 of 3 included studies
as not applicable to current health care. In conclusion, the
CR identifies preventive effects, but recommends interpreting
the results cautiously. The IQWiG report, which, unlike the CR,
comprises a dichotomised statement on benefit and harms,
regards the benefit of an ASB treatment as not proven due to
serious concerns regarding applicability.
Conclusion: Despite differences in detail, overall conclusions
regarding the effect of treatment do not differ much. Both
works see the need of further randomised trials. The main
difference is seen in the significance of applicability and
derived conclusions. To date there is no well-developed
methodology for assessing applicability. However, different
domains of applicability (population, setting, interventions,
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Background:Observational and experimental epidemiologic
studies thathaveaddressed the relationbetween intakeof the
trace element selenium and cancer risk have yielded strongly
conflicting results, as recently reportedbyaCochraneReview.
Most observational studies suggest an inverse association,
while randomized controlled trials (RCTs) have indicated a
null or direct relation. Little is known about the replication
of such inconsistencies when dealing with the risk of other
chronic disease. Objectives: We investigated the results
of observational and experimental studies linking selenium
exposure to theoccurrenceof type-2diabetes.Methods: After
a literature search, we identified 12 observational studies
(eight cross-sectional and four cohort) and five RCTs. Using
a random-effects model, we computed the summary relative
risk (RR) of type-2 diabetes along with its 95% confidence
interval (CI) in subjects with the highest versus the lowest
selenium exposure category in observational studies, and in
subjects allocated to selenium compared to placebo in the
RCTs. Results: Summary RRs were 1.98 (95% CI 1.22 to
3.23) and 1.13 (95% CI 0.15 to 8.45) for cross-sectional studies
using serum and toenail selenium for exposure assessment,
respectively. Cohortstudiesbasedontoenailseleniumyielded
a summary RR of 0.68 (0.72 to 0.98), while the only study
assessing dietary selenium intake gave a RR of 2.39 (1.32 to
4.32). For RCTs, summary RR was 1.10 (1.00 to 1.21) among
selenium-supplemented versus placebo. The distinctive
feature of the two observational studies (one cross-sectional
and one prospective) that failed to find an excess diabetes
risk associated with higher selenium exposure was that the
subjects were health professionals. Age, gender, study area
andother demographic characteristics didnot appear tohave
influenced the results. Conclusions: These results suggest
that the ability of observational studies to predict results of
RCTs when addressing the health effects of selenium may
differ on the basis of the outcome studied (diabetes versus
cancer) as well as the indicator used for exposure assessment
and the type of population under study.
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Aims: The Project on a Framework for Rating Evidence in
PublicHealth (PRECEPT) is a collaborationbetweenEuropean
public health agencies and universities, established in 2012,
that aims to establish a framework for evaluating and grading
evidence in the field of infectious disease epidemiology,
prevention and control. PRECEPT is funded by the European
Centre for Disease Prevention and Control (ECDC). This




priority in infectious disease prevention and control: disease
incidence/prevalence, risk factors fordisease, diagnosticsand
intervention. The framework is grouped into six consecutive
working steps, starting fromacomplex public health question
and ending with an evidence statement for each relevant
domain. In step 1, approaches are described for identification
of relevant questions. In step 2, methodological guidance
is provided for the conduct of systematic reviews for these
questions. For the appraisal of methodological quality of
identified individual studies, 15 different quality appraisal
tools are proposed and an algorithm is given to match a
given study design with an appropriate tool (step 3). In
step 4, a generalized evidence grading scheme based on
the GRADE methodology is provided to rate the quality of
bodies of evidence for each domain. The evidence appraisal
process ends with the preparation of evidence profiles and
summary of finding tables (step 5) followed by preparation
of an evidence summary for communication of the results
(step 6). By applying thismethodological framework, the user
should be able to evaluate and grade scientific evidence from
the four major domains in a transparent and reproducible
way. Outlook: The draft framework is currently being piloted
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